| Bioactivity | CCK antagonist 1 (compound 3d) is a CCK antagonist with IC50s of 1.1 μM and 4 μM for CCK1 and CCK2, respectively. CCK antagonist 1 can be used for research of cancer and mental disease[1]. |
| Target | IC50: 1.1 μM (CCK1), 4 μM (CCK2) |
| Name | CCK antagonist 1 |
| CAS | 742116-45-6 |
| Formula | C22H22N4O2 |
| Molar Mass | 374.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eric Lattmann, et al. Novel ureido - and amido-pyrazolone derivatives. Patent WO2004106306A1. [2]. Lattmann E, et al. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists. J Pharm Pharmacol. 2006 Mar;58(3):393-401. |
CCK antagonist 1
CAS: 742116-45-6 F: C22H22N4O2 W: 374.44
CCK antagonist 1 (compound 3d) is a CCK antagonist with IC50s of 1.1 μM and 4 μM for CCK1 and CCK2, respectively. CCK
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.